Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Equity Ratio (2024 - 2025)

Historic Equity Ratio for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to 0.62.

  • Prelude Therapeutics' Equity Ratio fell 2211.85% to 0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62, marking a year-over-year decrease of 2211.85%. This contributed to the annual value of 0.75 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Prelude Therapeutics' Equity Ratio stood at 0.62, which was down 2211.85% from 0.66 recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Equity Ratio peaked at 0.85 during Q1 2024, and registered a low of 0.62 during Q3 2025.